

Daily evidence digest

17 May 2021

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Mental health, Pfizer and AstraZeneca vaccine effectiveness in older adults, NHS England tackles surgical backlog

Peer reviewed journals featured:

- Systematic reviews on:
 - The global prevalence of mental health issues during COVID-19 [here](#)
 - Awake prone positioning in non-intubated patients with COVID-19 [here](#)
 - Reactogenicity, immunogenicity, and efficacy of SARS-CoV-2 vaccines [here](#)
- Observational studies on:
 - Effectiveness of Pfizer and AstraZeneca vaccines in older adults in England [here](#)
 - Clinical characteristics and outcomes of 12,306 paediatric COVID-19 patients [here](#)
- A modelling study on the public health impact of delaying the second dose of Pfizer or Moderna vaccine [here](#)
- Editorials on:
 - The effectiveness of England's initial vaccine roll out [here](#)
 - Vaccinating children against SARS-CoV-2 [here](#)
 - Repurposed drugs and COVID-19 [here](#)

Letters and correspondence discussed:

- COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia [here](#)

Pre-peer review articles featured:

- Clinical coding of post-acute COVID-19 syndrome in primary care in the UK [here](#)

Guidance and reports

- The TGA released its COVID-19 vaccine weekly safety report [here](#)
- The Australian Technical Advisory Group on Immunisation (ATAGI) released an update [here](#)

News and blogs

- NHS England is to trial rapid diagnostics and Saturday clinics to tackle elective care backlog [here](#)
- India sees record deaths as “black fungus” spreads fear [here](#)
- The global response was too slow and leadership absent [here](#)
- Fever, chills and aches more common when AstraZeneca and Pfizer vaccines are mixed [here](#)

[Click here](#) to subscribe to the daily evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on [COVID-19 transmission](#), SARS-CoV-2 [vaccines](#), and [variants](#) of concern.